newsfilter
← Latest News
GlobeNewswire·

Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update

HUMA
  • Breakthrough interim results from the V012 Phase 3 trial show ATEV outperformed AV fistula in female dialysis patients, with 91 more catheter-free days and significantly fewer infections.
  • Humacyte plans to file a supplemental Biologic License Application (sBLA) for ATEV dialysis access with the FDA during the second half of 2026.
  • The FDA accepted the Investigational New Drug (IND) application for the first-in-human CTEV study, with a Phase 2a trial for coronary artery bypass grafting expected to start in Q3 2026.
  • Second quarter 2026 sales of Symvess reached $0.4 million, an increase from $0.1 million in the same period of 2025.
  • Humacyte appointed James Mercadante as Chief Commercial Officer to lead the Symvess commercial strategy and Dr. Todd Rasmussen as Chief Surgical Officer.
  • The company raised $57.5 million from a public offering in June 2026 to fund commercialization, regulatory filings, and pipeline development.
  • A workforce restructuring in May 2026 reduced headcount by approximately 45 employees to achieve an estimated $14.3 million in annual net savings.
  • Humacyte reported a net loss of $36.8 million for the three months ended June 30, 2026, and $54.4 million for the six months ended June 30, 2026.
  • Cash, cash equivalents, and restricted cash totaled $80.3 million as of June 30, 2026.
  • The Israel Ministry of Health accepted the Marketing Authorization Application for Symvess for review with a 180-working-day timeline.
  • The FY 2026 U.S. Department of Defense Appropriations Act includes dedicated funding for the evaluation of bioengineered vascular repair technologies like Symvess.